Alcon Announces Results of 2022 Annual General Meeting
- Shareholders approve all proposals at the 2022 Annual
- Alcon welcomes Dr. Raquel C. Bono as newly-elected member of
Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care
dedicated to helping people see brilliantly, today announced the
approval of all proposed resolutions at its 2022 Annual General
As a result of the continuing tense situation due to the
coronavirus (COVID-19) pandemic, Alcon previously directed
shareholders to send their voting instructions to the independent
representative, Hartmann Dreyer Attorneys-at-Law.
A total of 339,496,103 shares with a nominal value of CHF 0.04
each, representing an aggregate nominal value of CHF 13,579,844.10
and 69.05% of the shares entitled to vote, are represented at
today's Annual General Meeting, all of them being represented by
Hartmann Dreyer, attorneys-at-law, Alcon’s independent
The Alcon shareholders voted for all proposals at the AGM,
including the election of Dr. Raquel C. Bono to the Board. “We are
delighted to welcome Dr. Bono to Alcon’s Board,” said F. Michael
Ball, the Chair of the Board of Directors. “Dr. Bono brings a
strong record of leadership in the healthcare industry, government
relations and regulatory public policy that will add greatly to the
expertise of our Board.” Dr. Bono is a board-certified trauma
surgeon and retired Vice Admiral, US Navy Medical Corps, as well as
the first Asian-American woman promoted to Vice Admiral.
Shareholders also re-elected F. Michael Ball as Chair of the
Board of Directors, and all members of the Board who stood for
re-election, namely Lynn Bleil, Arthur Cummings, David Endicott,
Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines
P�schel and Dieter Spälti, for a term of one year. In addition,
shareholders re-elected Thomas Glanzmann, Karen May and Ines
P�schel, and elected Scott Maw, to form the Compensation Committee
for a period of one year. The Board today also designated Karen May
as the Chair of the Compensation Committee with her re-election.
Discharge was granted to the members of the Board of Directors and
the members of the Executive Committee for the 2021 financial
In two separate binding votes, shareholders approved the maximum
aggregate amount of compensation of the Board of Directors for the
next term of office ending at the 2023 Annual General Meeting, and
the Executive Committee for 2023. Shareholders also accepted the
2021 Compensation Report, in a non-binding, consultative vote.
“I want to thank our shareholders for their high level of
engagement and participation in our Annual General Meeting, and for
their continued trust in our ability to lead the world in helping
people See Brilliantly,” said F. Michael Ball.
Alcon shareholders approved the operating and financial review
of Alcon Inc., the annual financial statements of Alcon Inc. and
the consolidated financial statements for 2021.
Shareholders also approved that a gross dividend of CHF 0.20 per
dividend-bearing share be declared, and that, after appropriation
of the proposed dividend, the remaining amount of available
earnings be carried forward.
Pricewaterhouse Coopers SA, Geneva, was re-elected as statutory
auditors for the 2022 financial year. Hartmann Dreyer
Attorneys-at-Law was also re-elected as the independent
representative for a term of one year extending until the 2023
Annual General Meeting.
Minutes of the meeting are available on Alcon’s Investor
Alcon will announce its first quarter 2022 earnings on May 10
after the close of the US markets, with an investor call scheduled
for May 11.
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 24,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
Connect with us on
version on businesswire.com: https://www.businesswire.com/news/home/20220427005833/en/
Investor Relations Dan
Cravens Allen Trang + 41 589 112 110 (Geneva) + 1 817 615 2789
(Fort Worth) email@example.com
Media Relations Lisa Gilbert
+ 41 589 112 111 (Geneva) + 1 817 615 2501 (Fort Worth)
Graphique Historique de l'Action
De Mai 2022 à Juin 2022
Graphique Historique de l'Action
De Juin 2021 à Juin 2022